Epidemiology and risk factors for mortality in critically ill patients with pancreatic infection
© 2023 The Author(s)..
Background: The AbSeS-classification defines specific phenotypes of patients with intra-abdominal infection based on the (1) setting of infection onset (community-acquired, early onset, or late-onset hospital-acquired), (2) presence or absence of either localized or diffuse peritonitis, and (3) severity of disease expression (infection, sepsis, or septic shock). This classification system demonstrated reliable risk stratification in intensive care unit (ICU) patients with intra-abdominal infection. This study aimed to describe the epidemiology of ICU patients with pancreatic infection and assess the relationship between the components of the AbSeS-classification and mortality.
Methods: This was a secondary analysis of an international observational study ("AbSeS") investigating ICU patients with intra-abdominal infection. Only patients with pancreatic infection were included in this analysis (n=165). Mortality was defined as ICU mortality within 28 days of observation for patients discharged earlier from the ICU. Relationships with mortality were assessed using logistic regression analysis and reported as odds ratio (OR) and 95% confidence interval (CI).
Results: The overall mortality was 35.2% (n=58). The independent risk factors for mortality included older age (OR=1.03, 95% CI: 1.0 to 1.1 P=0.023), localized peritonitis (OR=4.4, 95% CI: 1.4 to 13.9 P=0.011), and persistent signs of inflammation at day 7 (OR=9.5, 95% CI: 3.8 to 23.9, P<0.001) or after the implementation of additional source control interventions within the first week (OR=4.0, 95% CI: 1.3 to 12.2, P=0.013). Gram-negative bacteria were most frequently isolated (n=58, 49.2%) without clinically relevant differences in microbial etiology between survivors and non-survivors.
Conclusions: In pancreatic infection, a challenging source/damage control and ongoing pancreatic inflammation appear to be the strongest contributors to an unfavorable short-term outcome. In this limited series, essentials of the AbSeS-classification, such as the setting of infection onset, diffuse peritonitis, and severity of disease expression, were not associated with an increased mortality risk.ClinicalTrials.gov number: NCT03270345.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Journal of intensive medicine - 4(2024), 1 vom: 06. Jan., Seite 81-93 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dejonckheere, Marie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Intensive care unit |
|---|
| Anmerkungen: |
Date Revised 25.01.2024 published: Electronic-eCollection ClinicalTrials.gov: NCT03270345 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jointm.2023.06.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367543907 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367543907 | ||
| 003 | DE-627 | ||
| 005 | 20240125232139.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240124s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jointm.2023.06.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1270.xml |
| 035 | |a (DE-627)NLM367543907 | ||
| 035 | |a (NLM)38263964 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dejonckheere, Marie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Epidemiology and risk factors for mortality in critically ill patients with pancreatic infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT03270345 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). | ||
| 520 | |a Background: The AbSeS-classification defines specific phenotypes of patients with intra-abdominal infection based on the (1) setting of infection onset (community-acquired, early onset, or late-onset hospital-acquired), (2) presence or absence of either localized or diffuse peritonitis, and (3) severity of disease expression (infection, sepsis, or septic shock). This classification system demonstrated reliable risk stratification in intensive care unit (ICU) patients with intra-abdominal infection. This study aimed to describe the epidemiology of ICU patients with pancreatic infection and assess the relationship between the components of the AbSeS-classification and mortality | ||
| 520 | |a Methods: This was a secondary analysis of an international observational study ("AbSeS") investigating ICU patients with intra-abdominal infection. Only patients with pancreatic infection were included in this analysis (n=165). Mortality was defined as ICU mortality within 28 days of observation for patients discharged earlier from the ICU. Relationships with mortality were assessed using logistic regression analysis and reported as odds ratio (OR) and 95% confidence interval (CI) | ||
| 520 | |a Results: The overall mortality was 35.2% (n=58). The independent risk factors for mortality included older age (OR=1.03, 95% CI: 1.0 to 1.1 P=0.023), localized peritonitis (OR=4.4, 95% CI: 1.4 to 13.9 P=0.011), and persistent signs of inflammation at day 7 (OR=9.5, 95% CI: 3.8 to 23.9, P<0.001) or after the implementation of additional source control interventions within the first week (OR=4.0, 95% CI: 1.3 to 12.2, P=0.013). Gram-negative bacteria were most frequently isolated (n=58, 49.2%) without clinically relevant differences in microbial etiology between survivors and non-survivors | ||
| 520 | |a Conclusions: In pancreatic infection, a challenging source/damage control and ongoing pancreatic inflammation appear to be the strongest contributors to an unfavorable short-term outcome. In this limited series, essentials of the AbSeS-classification, such as the setting of infection onset, diffuse peritonitis, and severity of disease expression, were not associated with an increased mortality risk.ClinicalTrials.gov number: NCT03270345 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Intensive care unit | |
| 650 | 4 | |a Intra-abdominal infection | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Pancreatic infection | |
| 650 | 4 | |a Sepsis | |
| 700 | 1 | |a Antonelli, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Arvaniti, Kostoula |e verfasserin |4 aut | |
| 700 | 1 | |a Blot, Koen |e verfasserin |4 aut | |
| 700 | 1 | |a CreaghBrown, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a de Lange, Dylan W |e verfasserin |4 aut | |
| 700 | 1 | |a De Waele, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Deschepper, Mieke |e verfasserin |4 aut | |
| 700 | 1 | |a Dikmen, Yalim |e verfasserin |4 aut | |
| 700 | 1 | |a Dimopoulos, George |e verfasserin |4 aut | |
| 700 | 1 | |a Eckmann, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Francois, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Girardis, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Koulenti, Despoina |e verfasserin |4 aut | |
| 700 | 1 | |a Labeau, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Lipman, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Lipovestky, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Maseda, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Montravers, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Mikstacki, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Paiva, JoseArtur |e verfasserin |4 aut | |
| 700 | 1 | |a Pereyra, Cecilia |e verfasserin |4 aut | |
| 700 | 1 | |a Rello, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Timsit, JeanFrancois |e verfasserin |4 aut | |
| 700 | 1 | |a Vogelaers, Dirk |e verfasserin |4 aut | |
| 700 | 1 | |a Blot, Stijn |e verfasserin |4 aut | |
| 700 | 0 | |a Abdominal Sepsis Study (AbSeS) group on behalf of the Trials Group of the European Society of Intensive Care Medicine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of intensive medicine |d 2021 |g 4(2024), 1 vom: 06. Jan., Seite 81-93 |w (DE-627)NLM352660244 |x 2667-100X |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2024 |g number:1 |g day:06 |g month:01 |g pages:81-93 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jointm.2023.06.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2024 |e 1 |b 06 |c 01 |h 81-93 | ||